Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Hemophilia A is a rare bleeding disorder caused by a genetically encoded factor VIII mutation that affects blood clotting. sick...
Read Full NewsThe FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.
A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.
Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
1.
Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.
2.
Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care
3.
novel approach to test the toxicity of cancer drugs.
4.
Germline Profiling May Improve Risk Stratification in t-MNs
5.
In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.
1.
Uncovering the Mysteries of the RDW Blood Test
2.
Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment
3.
Task-Specific Conditioning During Cancer Rehabilitation: A Comprehensive Review
4.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
5.
Integrated Techniques in Oncology in the Digital Era
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Navigating the Complexities of Ph Negative ALL - Part V
2.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge